PyRx

PyRx performs high-throughput virtual screening and molecular docking to predict binding modes and binding affinities of small molecules against protein targets for computational drug discovery.

Key Features:

• Virtual screening capabilities: High-throughput virtual screening of compound libraries to identify molecules with potential therapeutic effects.
• Integration with molecular docking: Molecular docking to predict binding modes and estimate binding affinities of compounds to protein targets.

Scientific Applications:

• Glucokinase activator discovery: Used to screen and analyze libraries to identify novel symmetric pyridoxine moieties linked via sulfur-containing linkers as GK activators relevant to type 2 diabetes, with leading compounds showing ~150% and ~130% activation at 100 µM versus reference PF-04937319 and exhibiting low cytotoxicity and LD50 >2000 mg/kg in rats.
• Binding mode elucidation: Molecular docking studies were performed to model binding modes of active compounds and support comparative analysis with reference agent PF-04937319.

Methodology:

High-throughput virtual screening of compound libraries and molecular docking studies to predict binding modes and estimate binding affinities.